

## Posaconazole Suspension Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 04/09/2022  
4.9                10/01/2022              28749-00019            Date of first issue: 11/06/2014

---

### SECTION 1. IDENTIFICATION

Product name                                : Posaconazole Suspension Formulation  
Other means of identification            : No data available

#### Manufacturer or supplier's details

Company name of supplier                : Merck & Co., Inc  
Address                                        : 126 E. Lincoln Avenue  
    : Rahway, New Jersey U.S.A. 07065  
Telephone                                    : 908-740-4000  
Emergency telephone                      : 1-908-423-6000  
E-mail address                              : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use                         : Pharmaceutical  
  
Restrictions on use                        : Not applicable


---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Carcinogenicity (Inhalation)            : Category 2  
  
Reproductive toxicity                     : Category 2  
  
Specific target organ toxicity            : Category 1 (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms                        : 

Signal Word                                : Danger

Hazard Statements                        : H351 Suspected of causing cancer if inhaled.  
    : H361d Suspected of damaging the unborn child.  
    : H372 Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Precautionary Statements                : **Prevention:**  
    : P201 Obtain special instructions before use.  
    : P202 Do not handle until all safety precautions have been read and understood.  
    : P260 Do not breathe mist or vapors.  
    : P264 Wash skin thoroughly after handling.  
    : P270 Do not eat, drink or smoke when using this product.  
    : P280 Wear protective gloves, protective clothing, eye protection and face protection.

---

## Posaconazole Suspension Formulation

Version 4.9      Revision Date: 10/01/2022      SDS Number: 28749-00019      Date of last issue: 04/09/2022  
 Date of first issue: 11/06/2014

**Response:**

P308 + P313 IF exposed or concerned: Get medical attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents and container to an approved waste disposal plant.

**Other hazards**

None known.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Components**

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Glycerine	1,2,3-Propanetriol	56-81-5	$\geq 10 - < 30$ *
Posaconazole	No data available	171228-49-2	$\geq 1 - < 5$ *
Titanium dioxide	Titanic anhydride	13463-67-7	$\geq 0.1 - < 1$ *

\* Actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Diarrhea  
 Fever  
 Nausea  
 Headache  
 Vomiting

## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

---

Suspected of causing cancer if inhaled.  
 Suspected of damaging the unborn child.  
 Causes damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Prevent spreading over a wide area (e.g., by containment or oil barriers).  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
 For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
 Clean up remaining materials from spill with suitable absorbent.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

## Posaconazole Suspension Formulation

Version 4.9      Revision Date: 10/01/2022      SDS Number: 28749-00019      Date of last issue: 04/09/2022  
 Date of first issue: 11/06/2014

determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe the mist or vapors.  
 Do not swallow.  
 Avoid contact with eyes.  
 Avoid prolonged or repeated contact with skin.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store locked up.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Self-reactive substances and mixtures  
 Organic peroxides  
 Explosives  
 Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Glycerine	56-81-5	TWA (Mist)	10 mg/m <sup>3</sup>	CA AB OEL	
			TWA (Mist)	10 mg/m <sup>3</sup>	CA BC OEL
			TWA (Respirable mist)	3 mg/m <sup>3</sup>	CA BC OEL
			TWAEV (Mist)	10 mg/m <sup>3</sup>	CA QC OEL
Posaconazole	171228-49-2	TWA	300 µg/m <sup>3</sup> (OEB 2)	Internal	
Titanium dioxide	13463-67-7	TWA	10 mg/m <sup>3</sup>	CA AB OEL	
			TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
			TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
			TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL

## Posaconazole Suspension Formulation

Version 4.9      Revision Date: 10/01/2022      SDS Number: 28749-00019      Date of last issue: 04/09/2022  
 Date of first issue: 11/06/2014

		TWA (Respirable particulate matter)	2.5 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH
		TWA (Respirable particulate matter)	0.2 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Laboratory operations do not require special containment.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Combined particulates and organic vapor type

**Hand protection** : Chemical-resistant gloves

**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : suspension

**Color** : white

**Odor** : No data available

**Odor Threshold** : No data available

**pH** : 4.2 - 4.8

# SAFETY DATA SHEET



## Posaconazole Suspension Formulation

Version 4.9      Revision Date: 10/01/2022      SDS Number: 28749-00019      Date of last issue: 04/09/2022  
Date of first issue: 11/06/2014

---

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 1 g/cm<sup>3</sup>

Solubility(ies)  
Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

**Posaconazole Suspension Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/09/2022  
4.9                10/01/2022              28749-00019            Date of first issue: 11/06/2014

---

Conditions to avoid            : None known.  
Incompatible materials        : Oxidizing agents  
Hazardous decomposition     : No hazardous decomposition products are known.  
products

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity            : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Glycerine:**

Acute oral toxicity            : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity         : LD50 (Guinea pig): > 5,000 mg/kg

**Posaconazole:**

Acute oral toxicity            : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 3,000 mg/kg  
Acute dermal toxicity         : LD50 (Rat): > 2,000 mg/kg

**Titanium dioxide:**

Acute oral toxicity            : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity    : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species                        : Rabbit  
Result                         : No skin irritation

**Posaconazole Suspension Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/09/2022  
4.9                10/01/2022                28749-00019            Date of first issue: 11/06/2014

---

**Posaconazole:**

Species                                : Rabbit  
Result                                 : No skin irritation

**Titanium dioxide:**

Species                                : Rabbit  
Result                                 : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species                                : Rabbit  
Result                                 : No eye irritation

**Posaconazole:**

Species                                : Rabbit  
Result                                 : Mild eye irritation

**Titanium dioxide:**

Species                                : Rabbit  
Result                                 : No eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Posaconazole:**

Test Type                                : Magnusson-Kligman-Test  
Routes of exposure                        : Skin contact  
Species                                 : Guinea pig  
Result                                 : negative

**Titanium dioxide:**

Test Type                                : Local lymph node assay (LLNA)  
Routes of exposure                        : Skin contact  
Species                                 : Mouse  
Result                                 : negative

**Germ cell mutagenicity**

Not classified based on available information.



## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

---

### Components:

#### **Glycerine:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

#### **Posaconazole:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intravenous  
Result: negative

#### **Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

### **Carcinogenicity**

Suspected of causing cancer if inhaled.

### Components:

#### **Glycerine:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

#### **Posaconazole:**

Species : Rat  
Application Route : oral (feed)  
Exposure time : 2 Years

**Posaconazole Suspension Formulation**

Version 4.9      Revision Date: 10/01/2022      SDS Number: 28749-00019      Date of last issue: 04/09/2022  
Date of first issue: 11/06/2014

---

Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

**Titanium dioxide:**

Species : Rat  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 Years  
Method : OECD Test Guideline 453  
Result : positive  
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Posaconazole:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
General Toxicity Parent: NOAEL: 180 mg/kg body weight  
Symptoms: No effects on mating performance.  
Result: negative

Test Type: Fertility/early embryonic development  
Species: Rat, female  
General Toxicity Parent: NOAEL: 45 mg/kg body weight  
Symptoms: No effects on mating performance.  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat, female  
Application Route: Oral

## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

---

Developmental Toxicity: LOAEL: 29 mg/kg body weight  
Result: Fetotoxicity., Malformations were observed.

Test Type: Embryo-fetal development  
Species: Rabbit, female  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

### Components:

#### Posaconazole:

Routes of exposure : Ingestion  
Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Glycerine:

Species : Rat  
NOAEL : 0.167 mg/l  
LOAEL : 0.622 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 13 Weeks

Species : Rat  
NOAEL : 8,000 - 10,000 mg/kg  
Application Route : Ingestion  
Exposure time : 2 y

Species : Rabbit  
NOAEL : 5,040 mg/kg  
Application Route : Skin contact  
Exposure time : 45 Weeks

#### Posaconazole:

Species : Rat, female  
LOAEL : 5 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

**Posaconazole Suspension Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/09/2022  
4.9                10/01/2022              28749-00019            Date of first issue: 11/06/2014

---

Species                : Dog  
LOAEL                 : 3 mg/kg  
Application Route     : Oral  
Exposure time        : 392 Days  
Target Organs         : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species                : Monkey  
LOAEL                 : 15 mg/kg  
Application Route     : Oral  
Exposure time        : 1 Months  
Target Organs         : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species                : Dog  
LOAEL                 : 3 mg/kg  
Application Route     : Oral  
Exposure time        : 56 Weeks  
Target Organs         : Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species                : Monkey  
LOAEL                 : 180 mg/kg  
Application Route     : Oral  
Exposure time        : 12 Months  
Target Organs         : Blood, Gastrointestinal tract, spleen

Species                : Monkey  
LOAEL                 : 8 mg/kg  
Application Route     : Intravenous  
Exposure time        : 1 Months  
Target Organs         : Cardio-vascular system, Lungs, Adrenal gland, Blood

**Titanium dioxide:**

Species                : Rat  
NOAEL                 : 24,000 mg/kg  
Application Route     : Ingestion  
Exposure time        : 28 Days

Species                : Rat  
NOAEL                 : 10 mg/m<sup>3</sup>  
Application Route     : inhalation (dust/mist/fume)  
Exposure time        : 2 y

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Posaconazole:**

Ingestion             : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia,

## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

electrolyte imbalance

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### **Glycerine:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l  
Exposure time: 48 h
- Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

##### **Posaconazole:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.276 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.244 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility.
- Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

##### **Titanium dioxide:**

## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

---

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l Exposure time: 72 h
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

### Persistence and degradability

#### Components:

##### **Glycerine:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 92 % Exposure time: 30 d Method: OECD Test Guideline 301D
------------------	---	---

##### **Posaconazole:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
------------------	---	--

Stability in water	:	Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111
--------------------	---	---

### Bioaccumulative potential

#### Components:

##### **Glycerine:**

Partition coefficient: n-octanol/water	:	log Pow: -1.75
--	---	----------------

##### **Posaconazole:**

Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305
-----------------	---	---

Partition coefficient: n-octanol/water	:	log Pow: 4.15
--	---	---------------

### Mobility in soil

#### Components:

##### **Posaconazole:**

Distribution among environ-	:	log Koc: 5.52
-----------------------------	---	---------------

## Posaconazole Suspension Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 04/09/2022  
4.9                10/01/2022              28749-00019            Date of first issue: 11/06/2014

---

mental compartments

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues            : Dispose of in accordance with local regulations.  
Contaminated packaging        : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number                        : UN 3082  
Proper shipping name            : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Posaconazole)  
Class                                : 9  
Packing group                    : III  
Labels                              : 9

#### IATA-DGR

UN/ID No.                         : UN 3082  
Proper shipping name            : Environmentally hazardous substance, liquid, n.o.s.  
(Posaconazole)  
Class                                : 9  
Packing group                    : III  
Labels                              : Miscellaneous  
Packing instruction (cargo       : 964  
aircraft)  
Packing instruction (passen-    : 964  
ger aircraft)  
Environmentally hazardous     : yes

#### IMDG-Code

UN number                        : UN 3082  
Proper shipping name            : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Posaconazole)  
Class                                : 9  
Packing group                    : III  
Labels                              : 9  
EmS Code                         : F-A, S-F  
Marine pollutant                 : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Posaconazole)
Class	:	9
Packing group	:	III
Labels	:	9
ERG Code	:	171
Marine pollutant	:	yes(Posaconazole)

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## SECTION 16. OTHER INFORMATION

### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International



**Posaconazole Suspension Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
4.9	10/01/2022	28749-00019	Date of first issue: 11/06/2014

---

Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/01/2022  
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8